Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Curr Drug Targets. 2010 Dec;11(12):1504–1516. doi: 10.2174/1389450111009011504

Table 1.

Therapeutic Strategies Targeting HO-1 in Vascular Disease

  1. Enhancing Endogenous HO-1 Expression and/or Biological Activity

    • pharmacological or dietary induction of HO-1

    • gene delivery of HO-1

    • increasing substrate (heme) availability

    • administration of CO-sensitizing compounds

  2. Exogenous Delivery of HO-1 End Products

    • inhalation of CO

    • administration of CO-containing solutions

    • administration of prodrugs or CO-releasing compounds

    • administration of bile pigments

    • administration of CO and bile pigments

    • administration of CO and CO-sensitizing compounds

  3. Elevating Endogenous Bilirubin Levels

    • administration of uridine-diphosphate-glucuronyltransferase 1A1 inhibitors

  4. Inhibiting HO-1 Expression or Activity

    • administration of metalloporphyrins or imidazole-dioxolane compounds

    • use of HO-1 antisense technology

    • use of HO-1 small interference RNA technology